Comprehensive Systematic Review Update Summary: Disorders of Consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research by Giacino, J. T. et al.
SPECIAL ARTICLE
Comprehensive systematic review update
summary: Disorders of consciousness
Report of the Guideline Development, Dissemination, and Implementation
Subcommittee of the American Academy of Neurology; the American Congress of
Rehabilitation Medicine; and the National Institute on Disability, Independent
Living, and Rehabilitation Research
Joseph T. Giacino, PhD, Douglas I. Katz, MD, Nicholas D. Schiff, MD, John Whyte, MD, PhD, Eric J. Ashman, MD,
Stephen Ashwal, MD, Richard Barbano, MD, PhD, Flora M. Hammond, MD, Steven Laureys, MD, PhD,
Geoffrey S.F. Ling, MD, Risa Nakase-Richardson, PhD, Ronald T. Seel, PhD, Stuart Yablon, MD,








To update the 1995 American Academy of Neurology (AAN) practice parameter on persistent vegetative state
and the 2002 case definition for theminimally conscious state (MCS) by reviewing the literature on the diagnosis,
natural history, prognosis, and treatment of disorders of consciousness lasting at least 28 days.
Methods
Articles were classified per the AAN evidence-based classification system. Evidence synthesis occurred through
a modified Grading of Recommendations Assessment, Development and Evaluation process. Recom-
mendations were based on evidence, related evidence, care principles, and inferences according to the AAN
2011 process manual, as amended.
Results
No diagnostic assessment procedure had moderate or strong evidence for use. It is possible that a positive EMG
response to command, EEG reactivity to sensory stimuli, laser-evoked potentials, and the Perturbational
Complexity Index can distinguish MCS from vegetative state/unresponsive wakefulness syndrome (VS/UWS).
The natural history of recovery from prolonged VS/UWS is better in traumatic than nontraumatic cases. MCS
is generally associated with a better prognosis than VS (conclusions of low to moderate confidence in adult
populations), and traumatic injury is generally associated with a better prognosis than nontraumatic injury
(conclusions of low to moderate confidence in adult and pediatric populations). Findings concerning other
prognostic features are stratified by etiology of injury (traumatic vs nontraumatic) and diagnosis (VS/UWS vs
MCS) with low to moderate degrees of confidence. Therapeutic evidence is sparse. Amantadine probably
hastens functional recovery in patients with MCS or VS/UWS secondary to severe traumatic brain injury over
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In simplest terms, consciousness is defined as the state of
awareness of the self and environment.1 Conscious behavior
requires adequate arousal (i.e., wakefulness) and awareness of
content (i.e., sensory, cognitive, and affective experience).
Severe acquired brain injury (ABI) is a catastrophic event that
disrupts the brain’s arousal and awareness systems, which are
mediated by the brainstem and cortex, respectively. The most
severe injuries result in prolonged (i.e., lasting at least 28 days)
disorders of consciousness (DoC), including the vegetative
state (VS)2 and the minimally conscious state (MCS).3 VS is
also referred to as postcoma unawareness4 or unresponsive
wakefulness syndrome (UWS).5 In this guideline, the term
UWS is used synonymously with VS. While this term has no
special merit or mandate for use in clinical practice, it is in-
cluded here because of its wide acceptance in Europe. Table
e-1 (links.lww.com/WNL/A611) provides the definitions for
VS and MCS and other key terms pertinent to DoC.
The cost of lifetime care for persons with prolonged DoC can
exceed $1,000,000.6 Despite the enormity of the problem, few
practice guidelines are available. In 1995, the American
Academy of Neurology (AAN) published diagnostic and
prognostic guidelines for persistent VS (PVS)7 following an
evidence-based review completed by the Multi-Society Task
Force (MSTF) on PVS.2 In 2002, the Aspen Neurobehavioral
Workgroup defined MCS and published consensus-based
diagnostic criteria.3 Both reports focused on diagnosis, as data
addressing prognosis and treatment were sparse.
Based on available epidemiologic data,8 the annual US in-
cidence of VS is approximately 4,200 persons. The incidence
of MCS is unknown largely because it has no diagnostic code
in the International Classification of Diseases classification
system. Prevalence figures for VS/UWS and MCS in the
United States are hampered by economic factors that lead
patients with DoC to be transferred from the acute care set-
ting to long-term care facilities, where they are often lost to
follow-up. Prevalence estimates range from 5,000 to 42,000
persons for VS/UWS9–11 and 112,000 to 280,000 persons for
MCS using a proxy definition.12
Published estimates of misdiagnosis among patients with DoC
consistently approximate 40% in both US and European
studies.13–15 In the most recent study,13 41% of patients
with a clinical diagnosis of VS/UWS based on team consensus
(n = 44) were actually in MCS when reevaluated by the inves-
tigators using a standardized neurobehavioral scale. In addition,
89% of those with an uncertain diagnosis (n = 18) were found to
have clear signs of consciousness on standardized examination.
Findings from the other 2 studies14,15 were in the same direction.
Underlying visual or motor impairments interfering with de-
tection of command-following and failure to detect visual pursuit
are frequent causes of failure to recognize MCS. The rate of
diagnostic error underscores the need for more refined evalua-
tionmethods. This concern extends to the criteria for emergence
from MCS (eMCS), as some investigators suggest that the
existing criteria lead to overdiagnosis of this condition.16
Now is an opportune time to reevaluate current diagnostic
approaches. Apart from the extensive list of specialized neu-
robehavioral assessment instruments that have been released
since the MSTF and Aspen Neurobehavioral Workgroup
reports were published,2,17 a growing body of research sug-
gests that functional neuroimaging techniques, such as fMRI
and PET, may be able to detect suggestions of conscious
awareness in the absence of bedside evidence.18–21
Natural history studies of patients with prolonged DoC now
include outcomes extending beyond 1 year. This provides an
opportunity to reassess the 1994 MSTF introduction of the
term permanent VS (table e-1, links.lww.com/WNL/A611),
which is questioned based on themethodology used to calculate
the incidence of recovery of consciousness beyond 12months22
and the total number of individuals available for follow-up after
12 months (i.e., 30).23 Increasingly, publications are also avail-
able for DoC prognosis and treatment, with recent multicenter
randomized clinical trials available to determine the effective-
ness of specific interventions for patients with prolonged DoC.
The purpose of this systematic review and accompanying
guideline is to update the 1995 AAN PVS guideline7 and the
2002 MCS case definition.3 This article summarizes the sys-
tematic review findings and conclusions. The guideline rec-
ommendations are published separately.24 Full text of the
systematic review and guideline, including appendices e-1 to
e-9, is available as a data supplement at links.lww.com/WNL/
A610. Tables e-1 to e-3 and references e1 through e42, cited
here, are also available at links.lww.com/WNL/A612.
This review aimed to answer 10 clinical questions (table e-2,
links.lww.com/WNL/A611), which can be summarized in 4
Supplemental Data
Full text of guideline at:
NPub.org/m5ii8i
Glossary
AAN = American Academy of Neurology; CI = confidence interval; DoC = disorders of consciousness; eMCS = emergence
from minimally conscious state; LEP = laser-evoked potential; LR = likelihood ratio; MCS = minimally conscious state;
MSTF = Multi-Society Task Force; OR = odds ratio; PVS = persistent vegetative state; UWS = unresponsive wakefulness
syndrome; VS = vegetative state.
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overarching questions concerning patients with traumatic and
nontraumatic DoC: (1) What procedures accurately diagnose
prolonged DoC, where prolonged DoC is defined as lasting at
least 28 days? (2) What is the natural history of prolonged
DoC? (3) What factors or procedures help to predict out-
come in prolonged DoC? (4) What treatments are effective
for prolonged DoC?
Description of the analytic process
This systematic review and accompanying practice guideline
were developed in accordance with the process described in the
2011 AAN Clinical Practice Guideline Process Manual, as
amended.25 The full guideline provides a description of the
exact methodology followed, including the processes of con-
vening the author panel, performing the literature search, and
reviewing the evidence and application of a modified Grading
of Recommendations Assessment, Development and Evalua-
tion (GRADE) process.26 Recommendations were based not
only on the evidence in the systematic review, but also on
strong related evidence, established principles of care, and
inferences. The level of obligation for each recommendation
was based on the strength of these premises and the risk–
benefit ratio of following the recommendation, with adjust-
ments based on importance of outcomes, variation in patient
preferences, feasibility/availability, and patient costs. Consen-
sus was determined by a modified Delphi voting process in
accordance with prespecified rules.25
Inclusion criteria relevant for all questions were (1) pop-
ulation had a DoC for at least 28 days and (2) the study
enrolled at least 20 patients with a prolonged DoC. The 28-
day cutoff was employed to ensure that patients in coma were
excluded, as good outcome is not uncommon following
transient coma, unlike prolonged VS/UWS andMCS. Articles
were accepted only if the entire participant population met
the criterion of having a DoC for at least 28 days or if the
article presented data for this cohort separately. This ap-
proach was determined a priori and resulted in the exclusion
of some high-quality studies. This is discussed further in the
Putting the Evidence in a Clinical Context section.
Analysis of evidence
Diagnostic assessment
For the diagnostic question, the guideline panel considered
patients with traumatic or nontraumatic VS/UWS or MCS
at least 28 days postinjury and asked if any diagnostic as-
sessment procedures accurately detect behavioral signs of
consciousness or differentiate specific DoC compared with
standardized behavioral assessment. Readers are referred to
a previously published systematic review completed by the
American Congress of Rehabilitation Medicine Disorders of
Consciousness Task Force that provides evidence-based
recommendations for clinical use of standardized behavioral
assessment methods (work not repeated in this project).17
Study results were assessed using likelihood ratios (LRs),
which are described in the full-length guideline.
Eight diagnostic articles were Class I for at least some
procedures,27–34 4 articles were Class II,29,35–37 and 4 articles
were Class III38–40,e1 (links.lww.com/WNL/A612). No di-
agnostic assessment procedure had moderate or strong evi-
dence for use (table 1). For distinguishing VS and MCS, there
was insufficient evidence to support or refute the use of EMG
activity to command after adjusting for involuntary move-
ments,27 normal or mildly abnormal background on EEG,29,31
the combination of a low-voltage background EEG pattern and
lack of EEG reactivity,31 specific entropy measures,38 the ab-
sence of Aδ-fiber laser-evoked potential (LEP)N2P2 or C-fiber
LEP N2P2 components in response to LEPs,e2 evidence of
exogenous or endogenous attention as assessed by the P3a and
P3b components of P300 in response to word stimuli,35 a nasal
cannula “sniff controller,”28 command-following on an fMRI
motor imagery task,29 use of an fMRI incorrect-minus-correct
activation protocol,36 resting-state MRI,37 structural MRI,37 or
fluorodeoxyglucose-PET,37 often due to limited precision. It is
possible that fMRI using a word-counting task is not helpful in
distinguishing between MCS and VS (low confidence in the
evidence, 1 Class I study,33 with the LR+ suggesting no change
in the probability of MCS with testing and confidence intervals
(CIs) suggesting values of slight importance at most; LR+ 1.00,
95% CI 0.33–2.99). Results for this study were affected by the
fact that 3 of 8 patients diagnosed with VS/UWS based on the
absence of command following on the CRS-R had the sug-
gestion of fMRI activation with the task (37.5%, 95% CI
13.7%–69.4%), the implications of which are uncertain.
Natural history
Eighteen articlese3–e20 (links.lww.com/WNL/A612) met in-
clusion criteria for the natural history question. Results were
analyzed separately by DoC diagnosis and etiology; studies
only reporting mixed etiology populations are described in the
full-length guideline. No studies examined the natural history of
patients in traumatic or nontraumatic MCS in a manner
allowing outcome to be determined at specific times postinjury.
Natural history of patients with traumatic VS/UWS
Eight Class III studies were identified, reporting outcomes at 3
monthse4,e12,e20 (links.lww.com/WNL/A612), 6months,e4,e12,e20
8 months,e5 12 months,e4,e9,e10,e12,e20 and >24 monthse13
postinjury. Most studies were Class III due to recruitment
from specialty rehabilitation centers, thus limiting general-
izability. Results were combined in random-effects meta-
analyses to result in single estimates (table 2), each reflecting
low confidence in the evidence. Comprehensive results are
presented in the full-length guideline.
Natural history of patients with nontraumatic VS/UWS
Four Class III studies reported outcomes in patients with
nontraumatic VS/UWSe3,e5,e13,e14 (links.lww.com/WNL/
A612). Six- and 24-month recovery estimates are presented in
table 2. It is possible that 3-month survival for patients with
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nontraumatic VS/UWS is 80% (95% CI 67%–93%, I2 = 59)
(low confidence in the evidence, 2 Class III studies).e3,e13 It is
possible that 60% of patients with nontraumatic VS/UWS
(95% CI 45%–74%) will survive to 6–8 months (low confi-
dence in the evidence, 2 Class III studies).e3,e13
Prognostic assessment
For the prognostic question, the guideline panel first evalu-
ated the prognostic relevance of DoC diagnosis (VS/UWS vs
MCS) and of mechanism of injury. Then, the panel separately
considered prognostic factors in patients with traumatic or
nontraumatic VS/UWS or MCS at least 28 days postinjury
because this information has the most clinical relevance.
Prognostic factors for which there was insufficient evidence
are described only in the full-length guideline.
Prognostic factors in adult populations
Four Class II studiese6,e8,e21,e22 (links.lww.com/WNL/A612)
examined the prognostic value of diagnoses of MCS vs VS/
UWS. In prolonged DoC of traumatic origin, a diagnosis of
MCS, as opposed to VS/UWS, is probably associated with
increased odds of better than severe disability at 12 months
(moderate confidence in the evidence, 1 Class II studye22 with
increased confidence in the evidence due to magnitude of ef-
fect). In patients with prolonged DoC of mixed etiology, a di-
agnosis of MCS is possibly associated with increased odds of
improvement vs VS/UWS (odds ratio [OR] 4.72, 95% CI
1.13–19.71, I2 = 66%) (low confidence in the evidence, meta-
analysis of 3 Class II studiese8,e21,e22 with insufficient precision
to drive recommendations individually). In patients with
a prolonged DoC of mixed etiology already present for over
a year, a diagnosis of VS/UWS is possibly associated with
increased odds of deterioration in functional status over sub-
sequent years (OR 3.37, 95%CI 1.28–8.87) (low confidence in
the evidence, 1 Class II study).e6
One Class I and 4 Class II studies examined the prognostic
value of traumatic vs nontraumatic injury in patients with
prolonged DoCe6,e8,e21–e23 (links.lww.com/WNL/A612). In
patients with prolonged MCS, a traumatic etiology is prob-
ably associated with increased odds of better than severe
disability at 12 months (OR 11.0, 95% CI 1.9–63.2, moderate
confidence in the evidence, 1 Class II studye24 with increased
confidence in the evidence due to magnitude of effect).
In mixed populations including patients with MCS and
VS/UWS, traumatic DoC is probably associated with increased
odds of improvement (defined generally due to differences in
study design; OR 9.41, 95% CI 2.03–43.53; moderate confi-
dence in the evidence, 3 Class III studies,e8,e21,e24 2 of which
had sufficient precision on their owne21,e24 combined in ameta-
analysis with overall increased confidence in the evidence due
to magnitude of effect).
Table 1 Conclusions regarding diagnostic assessments with evidence for use in prolonged disorders of consciousness
(DoC)
Diagnostic assessment Conclusion
EMG In patients with a DoC for at least 28 days, a positive EMG response to command using a threshold of 1.5 on a ratio between
a response to motor commands and a control command to distinguish voluntary responses from involuntary movements is
possibly helpful in distinguishing patients with MCS from those with VS/UWS (LR+ 23.0, 95% CI 1.5–355.6) (low confidence in the
evidence, 1 Class I study34 with decreased confidence in the evidence due to precision).
EEG It is possible that EEG reactivity to at least one type of sensory stimulus distinguishes MCS from VS to amildly important degree
(low confidence in the evidence; 1 Class I study31 with decreased confidence in the evidence due to precision; LR+ 2.00, 95% CI
1.43–2.80).
Evoked potentials It is possible that the presence of Aδ-LEP N2P2 and C-LEP N2P2 components in response to LEPs distinguishes MCS from VS to
a mildly important degree (low confidence in the evidence; 1 Class I study32 with decreased confidence in the evidence due to
precision; LR+ 2.30, 95% CI 1.43–3.67).
PCI score It is possible that a PCI >0.31 distinguishes MCS from VS/UWS to a mildly important degree (low confidence in the evidence, 1
Class I study30 with decreased confidence in the evidence due to precision; LR+ 3.375, 95% CI 1.87–6.09).
Abbreviations: CI = confidence interval; LEP = laser-evoked potential; LR+ = positive likelihood ratio; MCS = minimally conscious state; PCI = Perturbational
Complexity Index; VS/UWS = vegetative state/unresponsive wakefulness syndrome.
Table 2 Cumulative recovery of consciousness in disorders of consciousness (DoC) lasting ≥28 days
Type of DoC 3 months 6 months 12 months 24 months
Posttraumatic VS/UWS 38% (29%–47%) 67% (58%–76%) 78% (69%–86%)
Nontraumatic VS/UWS 17% (5%–30%)a 7.5% (0%–24%)b
Abbreviation: VS/UWS = vegetative state/unresponsive wakefulness syndrome.
Values are % (95% CI).
a This meta-analysis included studies of patients 6–8 months postinsult.
b These estimates are for patients still in a DoC at 6months and reflects ameta-analysis of 2 studiese3,e13 (links.lww.com/WNL/A612) published 20 years apart
(1993 and 2013), with high heterogeneity in the meta-analysis.
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Prognostic factors for DoC subgroups are presented
in table 3, with measures of association described in
the full-length guideline. Nine studiese4,e10,e20,e22,e25–e29
(links.lww.com/WNL/A612) (1 Class I, 7 Class II, 1 Class III)
were identified looking at prognostic factors in patients with
traumatic VS/UWS, although 3 of the Class II studies were
based on largely the same patients/study and thus were con-
sidered together.e10,e25,e30 One Class II studye29 and 1 Class III
studye31 examined prognostic factors for patients with trau-
matic DoC in populations where patients in VS/UWS and
MCS were combined. Two Class I studiese14,e28 and 2 Class II
studiese3,e22 examined prognostic factors for patients with
Table 3 Prognostic features in disorders of consciousness (DoC) ≥28 days
Type of DoC
Prognostic factors associated with better prognosis Prognostic factors associated with worse prognosis
Moderate confidence Low confidence Moderate confidence Low confidence
Adult traumatic
VS/UWS
Higher-level activation of the
associated auditory cortex using BOLD
fMRI in response to a familiar voice
speaking the patient’s name






injury, or corona radiata injury on
MRI performed 6–8 weeks
postinjury
DRS scores of <26, 2–3 months
postinjury
Lower scores on the DRS
in general 2–3 months
postinjury
Fever of central origin in the acute
phase
Detectable P300 at 2–3 months
postinjury
The presence of P300
after controlling for DRS
and EEG reactivity
Diffuse body sweating in the acute
phase
Reactive EEG at 2–3 months postinjury Epilepsy in the late phase
Respiratory disturbance






Longer time post injury
at study enrollment
























score plus points for DoC
subtype
Older age
Presence of MMN on EEG Mental imagery fMRI Longer length of time postinjury
Increasing complexity of
sleep architecture on PSG
performed 3.5 ± 2months
postinjury
Abnormal early MLAEPs








Posttraumatic hyperthermia at any
time
Abbreviations: CRS-R = Coma Recovery Scale–Revised; DRS = Disability Rating Scale; MCS = minimally conscious state; MLAEP = middle latency auditory
evoked potential; MMN = mismatch negativity; SEP = somatosensory evoked potential; VS/UWS = vegetative state/unresponsive wakefulness syndrome.
a Some of these study cohorts are just patients with VS/UWS or MCS and some are mixed; see full guideline for details.
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nontraumatic VS/UWS. Only 1 prognostic studye28 was
identified for patients in either traumatic or nontraumatic
MCS; there was insufficient evidence to drive conclusions for
either group. Two Class I studies38,e5 and 7 Class II
studiese6,e8,21,e32–e35 examined prognostic factors in pop-
ulations with mixed etiologies (traumatic vs nontraumatic) or
mixed diagnoses (VS/UWS or MCS) or both in ways that
individual subgroups could not be distinguished (table 3).
Prognostic factors in pediatric populations
In pediatric patients, traumatic (vs anoxic) etiology of VS/UWS
present for at least 30 days is possibly associated with increased
odds of recovery at 3–12 months (low confidence in the
evidence, 1 Class II studye36 [links.lww.com/WNL/A612]). A
traumatic etiology, as compared to an anoxic injury, is probably
also associated with a better quality outcome (moderate confi-
dence in the evidence, 1 Class II studye36 with increased confi-
dence due to magnitude of effect). In pediatric patients with
aDoC for at least 90 days, a traumatic etiology, as comparedwith
an anoxic injury, is possibly associated with better cognitive and
motor outcomes and increased odds of taking feedings orally
(low confidence in the evidence, 1 Class II studye37). Other
prognostic features are described in table 3.
Therapeutic intervention
Two Class I therapeutic studiese38,e39 (links.lww.com/WNL/
A612) and 1 Class III therapeutic studye40 were identified.
Amantadine probably hastens functional recovery in patients
with MCS or VS/UWS secondary to severe traumatic brain
injury over 4 weeks of treatment (moderate confidence in the
evidence, 1 Class I studye38) and appears safe in this population.
There is insufficient evidence to support or refute continuation
of benefit once amantadine is discontinued (very low confi-
dence in the evidence, 1 Class I studye38 with insufficient
precision). In patients with VS/UWS of mixed etiologies,
conventional tilt table treatment is probably superior to tilt
table treatment incorporating an integrated stepping device for
improving level of arousal (moderate confidence in the evi-
dence based on 1 Class I studye39), but the benefit of tilt table
treatment vs placebo/nontreatment is not established (no
identified studies).
Putting the evidence in
a clinical context
The results of this systematic review highlight important gaps
in knowledge related to diagnosis, natural history, prognosis,
and treatment for patients with prolonged DoC. Some con-
sistent weaknesses in study methodology were observed
across studies, constraining the strength of the evidence.
Small sample size was the most prevalent weakness due to
limited study precision and generalizability.
In addition, the number of available studies was constrained by
the a priori inclusion criteria of the guideline. The decision to
include only studies investigating participants who were at least
28 days postinjury disqualified many studies conducted in the
acute care setting, as well as those that either combined, or did
not specify, the number of participants above and below this
threshold. Some well-designed studies in which the majority of
the participantsmet the 28-day inclusion criterion are considered
in the rationale for recommendations as strong related evidence
but could not contribute to the systematic review. Below, the
guideline panel describes trends in study design within each of
the 4 areas that compromised the strength of the evidence.
Diagnostic assessment
The most important challenge to validating more precise di-
agnostic approaches is the absence of an established reference
(gold) standard with adequate sensitivity and specificity. The
most commonly used reference standard (team consensus-
based diagnosis) is associated with a 30%–40% error rate.13–15
Thus, it is difficult to discern whether disagreement between
the reference standard and a novel assessment measure
reflects a false-positive or false-negative error on the part of
the novel measure, or evidence that the novel measure has
outperformed the reference standard. A second recurrent
weakness in diagnostic studies is the infrequent use of
masking procedures. Masking is essential to protect against
examiner bias, which is particularly important when the as-
sessment approach relies on nonobjective measures.
Natural history
Investigation of the natural history of recovery from severe
brain injury requires a systematic approach to tracking se-
lected milestones (e.g., mortality, recovery of consciousness,
improvement in degree of disability). Many of the studies
failed to report or control for the length of time from injury
and instead anchored follow-up to date of admission to the
inpatient rehabilitation setting. A study reporting that emer-
gence fromMCS occurs an average of 45 days after admission
to the rehabilitation hospital is of limited clinical utility if the
time to admission ranged from 4 to 52 weeks postinjury.
Studies often failed to stratify or subanalyze participants by
diagnostic subtype (VS/UWS vs MCS) and etiology
(traumatic/nontraumatic), obscuring the trajectory of re-
covery. The fact that most natural history studies enroll par-
ticipants at specialty rehabilitation centers is a further
limitation, as these results may not generalize to individuals
without access to specialty rehabilitation services.
Finally, relatively few natural history and prognostic studies
reported long-term functional outcomes. In many studies,
outcome assessment focused exclusively on recovery of con-
sciousness or eMCS or both, without attention to the corre-
sponding level of disability. Importantly, studies that tracked
functional outcome beyond 1 year suggest up to 1 in 5 patients
with prolonged DoC—especially those who transition toMCS
before 6months—eventually regain independence in the home
environmente41,e42 (links.lww.com/WNL/A612). DoC out-
come research will be of greater relevance to clinicians, patients,
and families by ensuring that results address the degree of
functional improvement attained.
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Prognostic assessment
The majority of studies investigating the predictive utility of
patient and injury characteristics were conducted retrospectively,
which subjected these studies to some of the same limitations
noted in the natural history studies. Because inclusion criteria did
not address specific clinical features known to be linked to
outcome (e.g., diagnostic subtype, injury etiology, and length of
time postinjury), within-sample variability tended to be high
along these dimensions, contributing to wide CIs and imprecise
outcome projection. In addition, risk factors and outcomes were
often not assessed independently, allowing the possibility that
factors believed to affect prognosis may have inappropriately
influenced clinical decisions and contributed to unfavorable
outcomes (including decisions to discontinue life-sustaining
care).
Therapeutic interventions
Most treatment studies were excluded because the in-
tervention was studied during the acute phase of recovery,
there was no control group, or the study was not methodo-
logically sound. DoC treatment studies face challenges not
encountered in clinical trials conducted in other populations.
First, the number of patients with prolonged DoC admitted to
inpatient rehabilitation settings has progressively declined
over the last 15 years. This trend is influenced by a number of
factors, including a tendency by insurers to preferentially
authorize rehabilitative care in lower-cost settings such as
skilled nursing facilities. Consequently, it is difficult to enroll
a large enough sample to support a sufficiently powered
therapeutic study. Constraints on sample size also limit
stratification of participants to account for differences in
treatment effect related to mediating factors such as cause of
injury, chronicity, and number of comorbidities.
A second challenge arises in the context of the rehabilitation
setting. The typical length of inpatient rehabilitation in many
academic medical centers has fallen below 20 days. Under
these circumstances, family members are often reticent to
enroll patients with prolonged DoC in a placebo-controlled
trial in view of the 50% likelihood of assignment to the pla-
cebo arm, preventing any possibility of active treatment dur-
ing rehabilitation apart from routine physical, occupational,
and speech therapies.
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